“During our second quarter we continued to make significant progress in both clinical and corporate goals, completing enrollment of our Phase 3 STRIVE-ON safety trial ahead of schedule and rebranding the Company to Grace Therapeutics (GRCE),” said Prashant Kohli, CEO of Grace Therapeutics. “With enrollment in the STRIVE-ON trial now complete, we anticipate a data readout in first calendar quarter of 2025, and remain on track to submit a New Drug Application, NDA, to the U.S. Food Drug Administration in the first half of calendar 2025. The potential benefits of GTx-104 in the treatment of aSAH will be highlighted in our Key Opinion Leader Webinar featuring Drs. Abhishek Ray and Andrew Webb on November 20th.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRCE: